|Bid||29.53 x 1100|
|Ask||29.66 x 800|
|Day's Range||29.14 - 33.12|
|52 Week Range||29.14 - 64.37|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 02, 2021 - Nov. 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.69|
In this Motley Fool Live video recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss three stocks to consider buying if the stock market sell-off worsens. Keith Speights: We're talking and we're nearly a full week into October right now, the stock market is off to a rocky start so far this month, quite a few biotech stocks and other healthcare stocks as well are down quite a bit already.
CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021. ANA Presentation Details:Sunday, October 17, 2021, 4:20 p
Clinical trial results expected this fall could send shares of these stocks screaming higher, or lower.